FDA demonstrated its heightened enforcement in the dietary supplement sector by identifying 17 firms from Miami to Malaysia making claims that products labeled as supplements will treat Alzheimer's disease, other neurological conditions as well as diabetes and cancer.
The Federal Trade Commission also signed onto warnings to three of the firms, according to the two